<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679896</url>
  </required_header>
  <id_info>
    <org_study_id>MAG-920-059</org_study_id>
    <nct_id>NCT04679896</nct_id>
  </id_info>
  <brief_title>Post Marketing Study of MagnetOs Putty Compared to Local Autograft in Patients Undergoing Posterolateral Lumbar Fusion</brief_title>
  <acronym>PARTNER</acronym>
  <official_title>A Prospective, Randomized, Single-center Study to Assess the Performance of MagnetOs Putty Compared to Local Autograft in Patients Undergoing up to Three-level Instrumented Posterolateral Lumbar Fusion (PLF).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuros Biosurgery AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthopaedic Institute of Western Kentucky</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Simplified Clinical Data Systems, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kuros Biosurgery AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV post-marketing study for MagnetOs Putty. MagnetOs Putty is a synthetic&#xD;
      bone graft extender product that is routinely used by surgeons as a treatment for patients&#xD;
      with leg pain and/or back pain and undergoing spinal fusion surgery.&#xD;
&#xD;
      In this study, MagnetOs Putty will be used according to the latest U.S. Instructions For Use,&#xD;
      specifically as a bone graft extender mixed with autograft in a 1:1 vol.% in the&#xD;
      posterolateral spine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, following a screening period of a maximum of 30 days, 30 patients will undergo&#xD;
      up to a three-level instrumented posterolateral fusion (PLF) procedure. Prior to surgery,&#xD;
      each patient will be randomized to receive MagnetOs Putty on the assigned side of the spine&#xD;
      and local autograft bone on the other at the diseased levels. They will be followed up at&#xD;
      discharge, Week 2, Week 6, Month 3, Month 6, and Month 12. An interim analysis will be&#xD;
      performed once 15 patients have completed their Month 6 visit and have measurements for the&#xD;
      endpoints available to measure effectiveness. The primary endpoint will be analyzed at Month&#xD;
      12.&#xD;
&#xD;
      In this study, MagnetOs Putty will be applied according to the latest Instructions for Use&#xD;
      approved in the United States. Specifically, MagnetOs Putty will be used as a bone graft&#xD;
      extender mixed with autograft in a 1:1 vol.% in patients with with leg pain and/or back pain&#xD;
      requiring up to three-level instrumented posterolateral lumbar fusion procedure. The fusion&#xD;
      procedure (PLF) will be left to the surgeon's discretion.&#xD;
&#xD;
      Radiographs will be obtained at Screening, Day 0, Week 6, Month 3. CT scans will only be&#xD;
      obtained at Month 6 and Month 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment Intra-patient control. Each patient serves as their own control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Fusion by CT Scan</measure>
    <time_frame>Month 12</time_frame>
    <description>The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic Fusion by Plain Radiographs</measure>
    <time_frame>Week 2, Week 6, Month 3</time_frame>
    <description>The rate of posterolateral lumbar fusion assessed by plain radiographs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posterolateral lumbar fusion assessed by CT-scan</measure>
    <time_frame>Month 6</time_frame>
    <description>The rate of posterolateral lumbar fusion assessed by CT-scan at Month 6. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interbody lumbar fusion assessed by plain radiographs</measure>
    <time_frame>Week 2, Week 6, Month 3, Month 6, Month 12</time_frame>
    <description>The rate of interbody lumbar fusion assessed by plain radiographs at Week 2, Week 6, Month 3, Month 6, and Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior vertebral bodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome by Oswestry Disability Index</measure>
    <time_frame>Week 2, Week 6, Month 3, 6, and 12</time_frame>
    <description>Change in functional score using Oswestry Disability Index questionnaire. Patient-completed survey provides subjective percentage score for level of function (disability) in activities of daily living. Score rage 0-100 percent. The lower the percentages indicate higher functionality; 0-20% minimal disability, 80-100% significant disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General, back and Leg Pain by Visual Analog Pain Scale</measure>
    <time_frame>Week 2, Week 6, Month 3, 6, and 12</time_frame>
    <description>Change in general, back and leg pain using Visual Analog Pain Scale score. The patient completed questionnaire is a unidimensional measure of pain intensity using a continuous scale comprised of a horizontal line 10 centimeters (100 mm) in length. The line is anchored by &quot;no pain&quot; (score of 0) and &quot;worst imaginable pain&quot;. A higher score indicates greater pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic Status by Physical Exam</measure>
    <time_frame>Week 2, Week 6, Month 3, 6, and 12</time_frame>
    <description>Change in neurologic status by examination to document stable, improved, or deficits in condition. Stable or improved findings for the lower extremities, specifically in reflexes, muscle strength, sensory, and straight leg raise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate</measure>
    <time_frame>Week 2, Week 6, Month 3, 6, and 12</time_frame>
    <description>Number of patients with secondary surgical interventions (SSI's) such as revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or removes part of the original implant configuration with or without replacement of the components within 12 months of surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Endpoint - number of patients with Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>The number of patients with Adverse Events from Screening up to Month 12 after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Endpoint - number of patients with Serious Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>The number of patients with Serious Adverse Events from Screening up to Month 12 after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Endpoint - number of patients with Adverse Device Effects</measure>
    <time_frame>12 Months</time_frame>
    <description>The number of patients with Adverse Device Effects from Screening up to Month 12 after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Endpoint - number of patients with Device Related Complications</measure>
    <time_frame>12 Months</time_frame>
    <description>The number of patients with any complications considered to device related with 12 months after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Economic - Duration of Surgery</measure>
    <time_frame>12 Months</time_frame>
    <description>Duration of surgery in minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Economic - Duration of Hospitalization</measure>
    <time_frame>12 Months</time_frame>
    <description>Duration of hospital stay in days</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Economic - Return to Work</measure>
    <time_frame>12 Months</time_frame>
    <description>Time to return to work in days</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Economic - Quality of Life</measure>
    <time_frame>Week 6, Month 3, 6, and 12</time_frame>
    <description>Change in Quality of Life measurement using EuroQol 5D/5L scoring</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Spine Fusion</condition>
  <arm_group>
    <arm_group_label>MagnetOs Putty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MagnetOs Putty use in instrumented posterolateral fusion, 7cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Local autograft</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MagnetOs Putty</intervention_name>
    <description>Procedure: Instrumented posterolateral spine fusion</description>
    <arm_group_label>Local autograft</arm_group_label>
    <arm_group_label>MagnetOs Putty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is able to read/be read, understand, and provide written informed consent and&#xD;
             has signed the Investigational Review Board (IRB) approved informed consent.&#xD;
&#xD;
          2. Male or female patient â‰¥ 18 years old.&#xD;
&#xD;
          3. Patients with leg pain and/or back pain requiring up to three-level instrumented&#xD;
             posterolateral lumbar fusion (L2 - S1).&#xD;
&#xD;
          4. Failed conservative treatment (physical therapy, bed rest, medications, spinal&#xD;
             injections, manipulations, or transcutaneous electrical nerve stimulation) for a&#xD;
             minimum period of 3 months prior to study enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Requires &gt; three-level fusion or expected to need secondary intervention within one&#xD;
             year following surgery.&#xD;
&#xD;
          2. To treat conditions in which general bone grafting is not advisable.&#xD;
&#xD;
          3. In conditions where the surgical site may be subjected to excessive impact or&#xD;
             stresses, including those beyond the load strength of fixation hardware (e.g. defect&#xD;
             site stabilization is not possible).&#xD;
&#xD;
          4. In case of significant vascular impairment proximal to the graft site.&#xD;
&#xD;
          5. In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta&#xD;
             or Paget's Disease) that affect bone or wound healing.&#xD;
&#xD;
          6. In case of acute and chronic infections in the operated area (soft tissue infections;&#xD;
             inflammation, bacterial bone diseases; osteomyelitis).&#xD;
&#xD;
          7. When intraoperative soft tissue coverage is not planned or possible.&#xD;
&#xD;
          8. Undergoing any procedure that allows MagnetOs to come in direct contact with the&#xD;
             articular space.&#xD;
&#xD;
          9. Receiving treatment with medication interfering with calcium metabolism.&#xD;
&#xD;
         10. Women who are or intend to become pregnant within the next 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Longlade, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kuros BioSciences B.V.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal Longlade, MD</last_name>
    <phone>+31622210098</phone>
    <email>pascal.longlade@kurosbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cesar Silva, MD</last_name>
    <email>cesar.silva@kurosbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orthopaedic Institute of Western Kentucky</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Strenge, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Degenerative Disc Disease</keyword>
  <keyword>Spine Fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

